Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: A case control study

BMC Gastroenterology

Volumn 14, Issue 1, 2014, Pages

  Peng, Cheng Yuan ^a   Chen, Ter Hsin ^b   Lim, Yun Ping ^c   Tsai, Fuu Jen ^c   Lin, Wei Yong ^c   Liao, Wen Ling ^c   Wan, Lei ^a,c,d  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

Hepatitis C virus; Interleukin 28B; Mannose receptor C; Standard of care treatment; Sustained virological response

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; MRC1 PROTEIN, HUMAN; VIRUS RNA;

ADULT; ARTICLE; FEMALE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HUMAN; IL 28B GENE; MAJOR CLINICAL STUDY; MALE; MRC 1 GENE; OUTCOME ASSESSMENT; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; IMMUNOLOGY; MIDDLE AGED; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; CASE-CONTROL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84902910139     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-14-113     Document Type: Article

References (33)

1. Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012, 19(7):449-464.
2. Gao B, Hong F, Radaeva S. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 2004, 39(4):880-890.
3. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461(7262):399-401.
4. Yu ML, Huang CF, Huang JF, Chang NC, Yang JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Li YN, Wu MS, Dai CY, Juo SH, Chuang WL. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 2011, 53(1):7-13.
5. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One 2011, 6(3):e18322.
6. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB, . Pharmacogenetics and Hepatitis C Meeting Participants Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology 2011, 53(1):336-345. Pharmacogenetics and Hepatitis C Meeting Participants.
7. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Günthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Müllhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY, . Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138(4):1338-1345. 1345 e1331-1337, Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study.
8. Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther 2012, 36(2):91-103.
9. Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L, Gao Z. Prediction of response to pegylated-interferon-alpha and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J 2012, 9:123.
10. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41(10):1100-1104.
11. Imran M, Waheed Y, Manzoor S, Bilal M, Ashraf W, Ali M, Ashraf M. Interaction of Hepatitis C virus proteins with pattern recognition receptors. Virol J 2012, 9(1):126.
12. Li K, Li NL, Wei D, Pfeffer SR, Fan M, Pfeffer LM. Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology 2012, 55(3):666-675.
13. Meyer K, Basu A, Ray R. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 2000, 276(1):214-226.
14. Gummuluru S, Rogel M, Stamatatos L, Emerman M. Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway. J Virol 2003, 77(23):12865-12874.
15. Cambi A, de Lange F, van Maarseveen NM, Nijhuis M, Joosten B, van Dijk EM, de Bakker BI, Fransen JA, Bovee-Geurts PH, van Leeuwen FN, Van Hulst NF, Figdor CG. Microdomains of the C-type lectin DC-SIGN are portals for virus entry into dendritic cells. J Cell Biol 2004, 164(1):145-155.
16. Cambi A, Gijzen K, de Vries JM, Torensma R, Joosten B, Adema GJ, Netea MG, Kullberg BJ, Romani L, Figdor CG. The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells. Eur J Immunol 2003, 33(2):532-538.
17. Op den Brouw ML, Binda RS, Geijtenbeek TB, Janssen HL, Woltman AM. The mannose receptor acts as hepatitis B virus surface antigen receptor mediating interaction with intrahepatic dendritic cells. Virology 2009, 393(1):84-90.
18. Famulski KS, Sis B, Billesberger L, Halloran PF. Interferon-gamma and donor MHC class I control alternative macrophage activation and activin expression in rejecting kidney allografts: a shift in the Th1-Th2 paradigm. Am J Transplant 2008, 8(3):547-556.
19. Hsu SC, Chen CH, Tsai SH, Kawasaki H, Hung CH, Chu YT, Chang HW, Zhou Y, Fu J, Plunkett B, Su SN, Vieths S, Lee RT, Lee YC, Huang SK. Functional interaction of common allergens and a C-type lectin receptor, dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN), on human dendritic cells. J Biol Chem 2010, 285(11):7903-7910.
20. Hattori T, Konno S, Takahashi A, Isada A, Shimizu K, Taniguchi N, Gao P, Yamaguchi E, Hizawa N, Huang SK, Nishimura M. Genetic variants in mannose receptor gene (MRC1) confer susceptibility to increased risk of sarcoidosis. BMC Med Genet 2010, 11:151.
21. Wang D, Feng JQ, Li YY, Zhang DF, Li XA, Li QW, Yao YG. Genetic variants of the MRC1 gene and the IFNG gene are associated with leprosy in Han Chinese from Southwest China. Hum Genet 2012, 131(7):1251-1260.
22. Alter A, de Leseleuc L, Van Thuc N, Thai VH, Huong NT, Ba NN, Cardoso CC, Grant AV, Abel L, Moraes MO, Alcaïs A, Schurr E. Genetic and functional analysis of common MRC1 exon 7 polymorphisms in leprosy susceptibility. Hum Genet 2010, 127(3):337-348.
23. Stephens M, Donnelly P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 2003, 73(5):1162-1169.
24. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001, 68(4):978-989.
25. Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001, 120(2):512-524.
26. Barnes E, Salio M, Cerundolo V, Francesco L, Pardoll D, Klenerman P, Cox A. Monocyte derived dendritic cells retain their functional capacity in patients following infection with hepatitis C virus. J Viral Hepat 2008, 15(3):219-228.
27. Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, Henneke P, Klein R, Paranhos-Baccala G, Depla E, Liang TJ, Blum HE, Baumert TF. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 2005, 105(9):3605-3614.
28. Rana D, Chawla YK, Duseja A, Dhiman R, Arora SK. Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment. Liver Int 2012, 32(7):1128-1137.
29. Kanazawa N. Dendritic cell immunoreceptors: C-type lectin receptors for pattern-recognition and signaling on antigen-presenting cells. J Dermatol Sci 2007, 45(2):77-86.
30. Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R. C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 2002, 76(13):6841-6844.
31. Kwan WH, Navarro-Sanchez E, Dumortier H, Decossas M, Vachon H, dos Santos FB, Fridman HW, Rey FA, Harris E, Despres P, Mueller CG. Dermal-type macrophages expressing CD209/DC-SIGN show inherent resistance to dengue virus growth. PLoS Negl Trop Dis 2008, 2(10):e311.
32. Lozach PY, Amara A, Bartosch B, Virelizier JL, Arenzana-Seisdedos F, Cosset FL, Altmeyer R. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 2004, 279(31):32035-32045.
33. Hashimoto Y, Ochi H, Abe H, Hayashida Y, Tsuge M, Mitsui F, Hiraga N, Imamura M, Takahashi S, Nelson Hayes C, Ohishi W, Kubo M, Tsunoda T, Kamatani N, Nakamura Y, Chayama K. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2011, 83(6):981-988.